Mohamed Elshazly

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5173294/publications.pdf

Version: 2024-02-01

29 papers	1,900 citations	516215 16 h-index	525886 27 g-index
31 all docs	31 docs citations	31 times ranked	2803 citing authors

#	Article	IF	Citations
1	Understanding Cardiology Practitionersâ€™ Interpretations of Electrocardiograms: An Eye-Tracking Study. JMIR Human Factors, 2022, 9, e34058.	1.0	7
2	A Blueprint for an AI & AR-Based Eye Tracking System to Train Cardiology Professionals Better Interpret Electrocardiograms. Lecture Notes in Computer Science, 2022, , 221-229.	1.0	2
3	Exercise Ventricular Rates, Cardiopulmonary Exercise Performance, and Mortality in Patients With Heart Failure With Atrial Fibrillation. Circulation: Heart Failure, 2021, 14, e007451.	1.6	3
4	Smart wearable devices in cardiovascular care: where we are and how to move forward. Nature Reviews Cardiology, 2021, 18, 581-599.	6.1	319
5	Atrial fibrillation catheter ablation complications in obese and diabetic patients: Insights from the US Nationwide Inpatient Sample 2005â€“2013. Clinical Cardiology, 2021, 44, 1151-1160.	0.7	8
6	Interpretation of a 12-Lead Electrocardiogram by Medical Students: Quantitative Eye-Tracking Approach. JMIR Medical Education, 2021, 7, e26675.	1.2	6
7	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. European Journal of Preventive Cardiology, 2020, 27, 1597-1605.	0.8	41
8	New Decade, New FDA Guidance for Diabetes Drug Development. Journal of the American College of Cardiology, 2020, 76, 2522-2526.	1.2	12
9	Role of Coronary Artery and Thoracic Aortic Calcium as Risk Modifiers to Guide Antihypertensive Therapy in Stage 1 Hypertension (From the Multiethnic Study of Atherosclerosis). American Journal of Cardiology, 2020, 126, 45-55.	0.7	6
10	Impact of riskâ€factor modification on arrhythmia recurrence among morbidly obese patients undergoing atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1979-1986.	0.8	11
11	Impact of Bariatric Surgery on Atrial Fibrillation Type. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007626.	2.1	30
12	Association Between Pre-Ablation Glycemic Control and Outcomes Among Patients With Diabetes Undergoing AtrialÂFibrillation Ablation. JACC: Clinical Electrophysiology, 2019, 5, 897-903.	1.3	57
13	Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation. Europace, 2019, 21, 1476-1483.	0.7	50
14	LDL-C Targets in Secondary Prevention: How Low Should We Go?. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	4
15	Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes. JAMA Cardiology, 2019, 4, 437.	3.0	59
16	Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. Circulation, 2018, 138, 244-254.	1.6	34
17	Warfarin Use Is Associated With Progressive Coronary Arterial Calcification. JACC: Cardiovascular Imaging, 2018, 11, 1315-1323.	2.3	44
18	Reimplantation After Lead Removal. Cardiac Electrophysiology Clinics, 2018, 10, 667-674.	0.7	4

#	Article	IF	Citations
19	Evaluating Precision Medicineâ€™s Ability to Improve Population Health. JAMA - Journal of the American Medical Association, 2017, 317, 440.	3.8	1
20	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. American Journal of Cardiology, 2016, 118, 647-655.	0.7	21
21	Non-HDL Cholesterol and Triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2220-2228.	1.1	119
22	Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. Atherosclerosis, 2016, 254, 78-84.	0.4	18
23	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology, 2015, 9, 511-518.e5.	0.6	5
24	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Nonâ€“High-Density Lipoprotein Cholesterol. Circulation, 2015, 132, 667-676.	1.6	41
25	Abstract 472: Prevalence of Fredrickson-Levy Dyslipidemia Phenotypes at Extreme HDL-C Levels: The Very Large Database of Lipids (VLDL-9B). Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0
26	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. JAMA - Journal of the American Medical Association, 2013, 310, 2061.	3.8	568
27	Nonâ€“High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. Journal of the American College of Cardiology, 2013, 62, 1960-1965.	1.2	59
28	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. Journal of the American College of Cardiology, 2013, 62, 732-739.	1.2	331
29	Very Large Database of Lipids: Rationale and Design. Clinical Cardiology, 2013, 36, 641-648.	0.7	39